Serum Concentration of Cystatin C and Risk of End-Stage Renal Disease in Diabetes Featured Article: Andrzej S. Krolewski, M.D., Ph.D., James H. Warram,

Slides:

Advertisements

Similar presentations

The National Kidney Foundations Kidney Early Evaluation Program TM The National Kidney Foundations Kidney Early Evaluation Program TM Essex-Passaic Wellness.

Advertisements

Diabetes, Anemia and Chronic Kidney Disease Josephine Carlos-Raboca,M.D., F.P.S.E.M., Endocrinology, Diabetes and Metabolism Makati Medical Center.

Diabetic Nephropathy.  Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes.  In 2001, 41,312 people with diabetes began.

Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT): Urinary Screening and Baseline Biochemical and Cardiovascular Assessments Featured.

Mugendi AG, BPharm, MPharm (Clin Pharm). Comparison of the effects of losartan and enalapril on renal function in adults with chronic kidney disease at.

Severe Hypoglycemia and Mortality After Cardiovascular Events for Type 1 Diabetic Patients in Sweden Featured Article: Tom W.C. Lung, Dennis Petrie, William.

6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.

Cystatin C– and Creatinine-Based Estimated Glomerular Filtration Rate, Vascular Disease, and Mortality in Persons With Diabetes in the U.S. Featured Article:

Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.

Subarachnoid Hemorrhage in Type 1 Diabetes A prospective cohort study of 4,083 patients with diabetes Featured Article: Miikka Korja, M.D., P.H.D., Lena.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

Diabetic nephropathy is a clinical syndrome.

Diabetes and Cause-Specific Mortality in a Prospective Cohort of One Million U.S. Adults Featured Article: Peter T. Campbell, Ph.D., Christina C. Newton,

Predicting Progression in Diabetic Nephropathy: New Biomarker: sTNFR1* Circulating soluble Tumor Necrosis Factor Receptor 1.

Trial profile Mann JF et al. Lancet 2008;372:

High Concentrations of AGE-LDL and Oxidized LDL in Circulating Immune Complexes Are Associated With Progression of Retinopathy in Type 1 Diabetes Featured.

Short- and Long-Term Mortality After Myocardial Infarction in Patients With and Without Diabetes Featured Article: Sjoerd T. Nauta, M.S.C., Jaap W. Deckers,

Updates in Diabetic Nephropathy Rodica Pop-Busui, M.D., Ph.D Division of Metabolism, Endocrinology and Diabetes Michigan Comprehensive Diabetes Center.

Am J Kidney Dis. 2014;63(6): R3 박세정 /prof. 이태원 Comparative Effectiveness of Early Versus Conventional Timing of Dialysis Initiation in Advanced.

The FRET Study Source: Inoue T, Ikeda H, Nakamura T, et al. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin.

Date of download: 6/23/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Sickle Cell Trait With Chronic Kidney.

Celiac Disease Increases Risk of Thyroid Disease in Patients With Type 1 Diabetes: A Nationwide Cohort Study Featured Article: Matthew Kurien, Kaziwe Mollazadegan,

내과 R1 문정락 / prof. 정경환 N Engl J Med 369;10 nejm.org 932 september 5, 2013.

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes Hermann Haller, M.D., Sadayoshi Ito, M.D., Ph.D., Joseph L. Izzo.Jr., M.D.,

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.

The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

The LIVES Sub-analysis

Chronic Kidney Disease in Diabetes

Melody Sherwood, Peter A McCullough The Lancet Global Health

Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD Akshay S. Desai, MD, MPH,

Persistent High Serum Bicarbonate and the Risk of Heart Failure in Patients With Chronic Kidney Disease (CKD): A Report From the Chronic Renal Insufficiency.

Differential Estimation of CKD Using Creatinine- Versus Cystatin C–Based Estimating Equations by Category of Body Mass Index Suma Vupputuri, PhD, Caroline.

Renal function and outcome after heart transplantation

Diagnosis and Management of Chronic Kidney Disease

Urinary ammonia and long-term outcomes in chronic kidney disease

Volume 85, Issue 5, Pages (May 2014)

Estimating GFR Using the CKD Epidemiology Collaboration (CKD-EPI) Creatinine Equation: More Accurate GFR Estimates, Lower CKD Prevalence Estimates, and.

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Volume 92, Issue 1, Pages (July 2017)

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Volume 68, Issue 6, Pages (December 2015)

The predictive value of s-cystatin C for mortality after coronary artery bypass surgery Alain Dardashti, MD, PhD, Shahab Nozohoor, MD, PhD, Lars Algotsson,

Volume 79, Issue 12, Pages (June 2011)

Health ABC: Mortality risk by quintile of cystatin C

Cardiovascular Disease and CKD: Core Curriculum 2010

Chronic Kidney Disease in Diabetes

Melody Sherwood, Peter A McCullough The Lancet Global Health

GFR Estimation: From Physiology to Public Health

Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP) Richard.

A New Clinical Prediction Tool for 5-Year Kidney Transplant Outcome

Refinement of survival prediction in patients undergoing lower extremity bypass surgery: Stratification by chronic kidney disease classification Christopher.

Advances in CKD Detection and Determination of Prognosis: Executive Summary of the National Kidney Foundation–Kidney Early Evaluation Program (KEEP) 2012.

I. Introduction American Journal of Kidney Diseases

Your Kidneys May Outlive You

GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration

Utility and Validity of Estimated GFR–Based Surrogate Time-to-Event End Points in CKD: A Simulation Study Tom Greene, PhD, Chia-Chen Teng, MS, Lesley.

Glycemic Status and Mortality in Chronic Kidney Disease According to Transition Versus Nontransition to Dialysis Connie M. Rhee, MD, MSc, Csaba P. Kovesdy,

Volume 63, Issue 4, Pages (April 2003)

Predictors of disease progression in patients with CKD

Volume 84, Issue 5, Pages (November 2013)

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation? Pantelis A. Sarafidis, Luis.

Within-Person Variability in Kidney Measures

(G) Body mass index (BMI) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (G) Body mass index (BMI) values.

Volume 83, Issue 3, Pages (March 2013)

Michael R. Lattanzio, Matthew R. Weir Kidney International

Volume 88, Issue 5, Pages (November 2015)

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Correlations among chronic kidney disease (CKD) classification, urinary adiponectin level, eGFR, and ACR. (A) Correlation between CKD classification and.

Presentation transcript:

Serum Concentration of Cystatin C and Risk of End-Stage Renal Disease in Diabetes Featured Article: Andrzej S. Krolewski, M.D., Ph.D., James H. Warram, M.D., S.C.D., Carol Forsblom, D.M.S.C., Adam M. Smiles, M.S., Lena Thorn, M.D., D.M.S.C., Jan Skupien, M.D., Ph.D., Valma Harjutsalo, Ph.D., Robert Stanton, M.D., John H. Eckfeldt, M.D., Ph.D., Lesley A. Inker, M.D., M.S., F.R.C.P.(C), Per- Henrik Groop, M.D., D.M.S.C. Diabetes Care Volume 35: November, 2012

STUDY OBJECTIVE To examine whether predicting end-stage renal disease (ESRD), according to chronic kidney disease (CKD) staging by creatinine-based estimates of the glomerular filtration rate (eGFRcreat), is improved by further staging with serum cystatin C–based estimates (eGFRcyst) Krolewski A et al. Diabetes Care 2012;35:

STUDY DESIGN AND METHODS Patients with diabetes in CKD stages 1–3 were selected from three cohorts: o Two from Joslin Diabetes Center (one with type 1 diabetes [N = 364] and one with type 2 diabetes [N = 402]) o One from the Finnish Diabetic Nephropathy (FinnDiane) Study of type 1 (N = 399) Baseline serum concentrations of creatinine and cystatin C measured in all patients Follow-up averaged 8–10 years Onsets of ESRD (n = 246) and death unrelated to ESRD (n = 159) were ascertained Krolewski A et al. Diabetes Care 2012;35:

RESULTS Patients given a higher stage by eGFRcyst than eGFRcreat had significantly higher risk of ESRD than patients with concordant staging in all three cohorts (hazard ratio 2.3 [95% CI 1.8–3.1]) Patients at a lower stage by eGFRcyst than by eGFRcreat had lower risk than patients with concordant staging (0.30 [0.13–0.68]) Deaths unrelated to ESRD followed the same pattern, but differences were not as large Krolewski A et al. Diabetes Care 2012;35:

CONCLUSIONS CKD staging based on eGFRcyst significantly improves ESRD risk stratification based on eGFRcreat Krolewski A et al. Diabetes Care 2012;35: